Nyxoah S.A.(NYXH)

Medical - Specialties · Mont-Saint-Guibert, WA

$1.43+0.02 (+1.42%)

Delayed quote: Oct 6, 2026, 11:24 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:28:03.084Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:28:03.084Z.

Quote observation: 2026-10-06T15:24:25.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 143,104,125
Total debt · period ending 2026-06-30: 60,042,118.24
Cash · period ending 2026-06-30: 73,230,870.7
TTM free cash flow · period ending 2026-06-30: -85,721,115.87031

FMP input reference: 88249fb6bbade3b4ad802b4bad00c79a42ee89cc3a650020707e3f27628c9d48

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NYXH EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

NYXH Competitors' EV/FCF Ratio

NYXH

Nyxoah S.A.

Current

Market Cap

$143.10M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AIRS

AirSculpt Technologies, Inc.

vs NYXH

Market Cap

$141.80M

EV/FCF Ratio

254.53x

TTM Avg

151.93x

3Y Avg

133.72x

5Y Avg

94.60x

ACOG

Alpha Cognition Inc

vs NYXH

Market Cap

$140.02M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMRX

Immuneering Corporation

vs NYXH

Market Cap

$146.30M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FBIOP

Fortress Biotech, Inc.

vs NYXH

Market Cap

$139.73M

EV/FCF Ratio

0.06x

TTM Avg

3.71x

3Y Avg

3.71x

5Y Avg

3.71x

KRSA

Korsana Biosciences, Inc.

vs NYXH

Market Cap

$147.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NGEN

NervGen Pharma Corp. Common stock

vs NYXH

Market Cap

$147.54M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFMDP

LifeMD, Inc.

vs NYXH

Market Cap

$147.97M

EV/FCF Ratio

N/A

TTM Avg

175.94x

3Y Avg

1237.69x

5Y Avg

1237.69x

KRMD

KORU Medical Systems, Inc.

vs NYXH

Market Cap

$136.88M

EV/FCF Ratio

500.37x

TTM Avg

1051.55x

3Y Avg

1051.55x

5Y Avg

1051.55x

ABOS

Acumen Pharmaceuticals, Inc.

vs NYXH

Market Cap

$150.59M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Nyxoah S.A. (NYXH)	$143.10M	N/A	N/A	N/A	N/A
AirSculpt Technologies, Inc. (AIRS)vs ›	$141.80M	254.53x	151.93x	133.72x	94.60x
Alpha Cognition Inc (ACOG)vs ›	$140.02M	N/A	N/A	N/A	N/A
Immuneering Corporation (IMRX)vs ›	$146.30M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIOP)vs ›	$139.73M	0.06x	3.71x	3.71x	3.71x
Korsana Biosciences, Inc. (KRSA)vs ›	$147.49M	N/A	N/A	N/A	N/A
NervGen Pharma Corp. Common stock (NGEN)vs ›	$147.54M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMDP)vs ›	$147.97M	N/A	175.94x	1237.69x	1237.69x
KORU Medical Systems, Inc. (KRMD)vs ›	$136.88M	500.37x	1051.55x	1051.55x	1051.55x
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$150.59M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

NYXH EV/FCF Ratio Metrics

NYXH Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics